Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C200806

C200806

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

GDC

A recombinant humanized bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIGIT/anti-PD-L1 bispecific antibody PM1022 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT, which is expressed on various immune cells and particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.

Anti-TIGIT/Anti-PD-L1 Bispecific Antibody PM1022

Anti-PD-L1/TIGIT Bispecific Antibody PM1022

PD-L1 x TIGIT Bispecific Antibody PM 1022

PM1022

PM-1022

PM 1022

Anti-TIGIT/PD-L1 Bispecific Antibody PM1022

Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022

TIGIT x PD-L1 Bispecific Antibody PM1022

Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022

813136

Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022

Thesaurus:C200806

Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022

Pharmacologic Substance

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909